Targets becoming a leading supplier of active pharmaceutical ingredients and formulated products
Following its most successful year to date, Aesica Pharmaceuticals is set almost to double in size and has expanded into new markets. The company’s vision is to become the world’s leading supplier of active pharmaceutical ingredients and formulated products and recent developments could enable Aesica to achieve this, and quickly.
As one of the fastest growing companies in the UK, Aesica has increased turnover by more than 300% in the last five years and was ranked 3rd in Deloitte’s 2011 Buyout Track 100 as published in The Sunday Times.
2010 was also a year of significant expansion for Aesica, as it acquired Nottingham-based R5 Pharmaceuticals in June and more recently announced the acquisition of three European sites from Belgian pharmaceutical firm, UCB. In addition, new business development managers were recruited for San Diego and New York in preparation for further expansion across America.
The European acquisitions, which include a long-term strategic partnership with UCB, have resulted in Aesica doubling its workforce to approximately 1,300 staff. As a result of this and planned future developments, by 2013 Aesica predicts sales of £300m.
Robert Hardy, chief executive of Aesica, said since Aesica was founded in 2004 the company has worked strategically to expand its offering and market reach while consolidating its client portfolio.
‘While we have experienced rapid growth, the contract manufacturing market also continues to experience significant growth and increasing numbers of pharmaceutical and biotechnology companies are recognising the benefits of outsourcing their drug manufacturing requirements. As companies look for greater flexibility, swifter commercialisation, minimal capital expenditure and lower scale up costs, our expertise and proven track record in delivering a full service offering is enabling us to increase our market share and reach new markets,’ he added.
‘Now we are looking at new ways of adding value to our offering through the development of new high containment facilities to complement our high potency capability.’
Hardy said Aesica’s vision has always been to become the leading supplier of active pharmaceutical ingredients and formulated products to the global pharmaceutical and biotechnology industries.
‘Following the success of 2010 we have secured a greater market share, taking us one step closer to achieving this ambition,’ he added.